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capsid antigen (VCA) IgG status retrospectively. The EBV IgM status 
was determined h m  6 weeks post transplant in EBV IgG negative 
recipients. 
Results: 366 donorlrecipient pairs were tested for EBV IgG. 
12 patients lacking sdicient specimen for testing were excluded. 
Of the 366 cases tested, 330 (90%) both recipient and donor were 
found to be EBV IgG positive, 27 (7%) recipient EBV IgG positive 
and donor EBV IgG negative, 2 (1%) both recipient and donor EBV 
IgG negative. 7 (2%) were EBV IgG negative but received organs 
&om EBV IgG positive donors. 3 patients sen-converted to EBV 
I@, 2 patients remain EBV IgM negative. F'TLD was dmgnosed in 
12 (3%) of the 366 patients of which only 1 was EBV IgG negative 
but received an organ h m  a EBV IgG positive donor. This pa- 
tient sem-converted to EBV IgM positive 4 months post transplant, 
shortly before the +osis of PTLD. Of the 11 patients with PTLD 
who were EBV IgG positive preuansplant, 9 received organs h m  
positive donors. Serological evidence of EBV reactivation could be 
demonstrated in 7 (53%) of these patients shortly before the dmgno- 
sis of PTLD. No s imcan t  dXerence in the incidence of PTLD was 
found between both groups (p > 1). 
Conclusions: 1. EBV matching does not reduce the incidence of 
PTLD 2. Changes in EBV serology are not predictive of subsequent 
PTLD. 
(p10431 Infections in the lntrathoracic Organ 
Transplantation 
F! Suwangool, F!P Suwangool. Chulalongkorn University Hospital, 
Bangkok, Thailand 
Objective: To study the cause of death due to infection in intratho- 
racic organ transplantation. 
Methods: Prospective study all cases, by cultures, biopsies, 
necropsies or autopsies. 
Infection is a major complication and cause of death in organ 
transplantation. By December 1996, 36 heart transplantation, 13 
heart-lung and 6 lung transplantations had been performed at Chu- 
lalongkorn Hospital. In study of infections in the biopsies, necmpsies 
and autopsies of these patients, disseminated tuberculosis was seen in 
2 patients, one in heart transplant who lived 20 months after oper- 
ation, the other was a lung transplant who suMved 2 years and 2 
months following operations. Nocardia brain abscess was seen in one 
heart transplant patient. The other had severe-extensive bronchop- 
neumonia. Severe pneumonia was seen in 5 heart-lung aansplant, 3 
of these had CMV. Aspergdlosis was present in 3 patients, 2 of which 
also associated with CMV. Five of 6 lung transplant patients died of 
severe bacterial pneumonia, one of these had associated aspergdlosis. 
Conclusion: CMV and bacted pneumonia was the common 
cause of deaths. 
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I P10441 Induction of Immune Responses Against HIV-1 
Reverse Tmnscriptase by DNA Immunization 
M. Isaguhants 3,  S. Gudima ', M. Levi ', 0. Ivanova ' , 
D. Pokholok ', M. Garaev 
B. Wahren'. 'Iwtwvsky Institute of Krolw, Stockholm, Sweden, 
*Engelgardt Institute of Molecular Siolw, Moscow, Russia, 'Swedish 
Institute for Injiectious Diseaw Control, Stockholm, Sweden 
Objective: To induce immune responses ag&t HIV-1 reverse uan- 
scripmse. 
S. Kochetkov ', U. RudEn ', 
Methods: Plasmid DNA was constructed encoding HN-1 RT 
(66 kDa) under the control of CMV promoter (RT-DNA). Rabbits 
were immunized by intramascular injection of RT-DNA. A refer- 
ence immunization was done with p66 expressed in E coli. Immune 
responses were studied by ELISA, immunoblot, and PBMC prolif- 
eration tests using p66 and synthetic peptides. 
Results: DNA immunization induced potent humoral and cellu- 
lar anti RT responses. Mer 2 months anti RT titers reached 1:7000. 
Anti RT sera reacted with RT in immunoblot. Punfied anti RT IgG 
inhibited up to 30% of RT activity. Similar responses were induced 
by p66, but their fine specificity was di6erent: 
Epitope type Aa B-cell response T-cdl mponrc 
RTDNA p 6 6  R'CDNA p66 
CD4+- 36- 52 ++ +++ late 
Th 157-179 + ++ late C X l Y  
216290 ++ - cvly cvly 
375-389 - + klfc MN 
411425 ++ ++ ktc euty 
CTL 267-27 + - late M1V 
514-528 f f lo* MN 
291-305 f + hte htc 
341-356 + + late htc 
442425 ++ - late htc 













Conclusions: Potent anti HIS-1 immune response of unique 
fine specificity was induced by immunization with DNA encoding 
HN-1 reverse tnnscriptase 
I PI045 I The Effect of Hib Immunization on H N  Viremia 
D. Dockrell 
S. Strickland *, C. Pomeny ', D. Persing 
'University ofMinnesoto, USA, 3Univem'ty of Kentub  USA 
Background: Cellular activation may increase HIV viral replica- 
tion and therefore viremia. Immunization of HIV-positive persons 
is recommended a p m t  infiuenza, pneumococcus and Haemophitus 
inauenzae Type b (Hib). Recent reports suggest that antigenic stirnu- 
lation caused by vaccines may lead to increased H N  viral replication 
and viral load. In this study we examined whether Hib immuniza- 
tion had any sigdicant effect on HIV RNA copy number, CD4 
count or p24 antigen levels one month after receiving one of three 
licensed Hib-conjugate vaccines. 
Methods: We retmspectively analyzed sera h m  53 HIS-positive 
individuals enrolled in a Hib-conjugate vaccine study. Subjects ran- 
domly received one dose of one of three licensed Hib-conjugate 
vaccines (Connaught, Merdc or Lederle). HIV RNA copy num- 
ber was determined by RT-PCR using the HIV Monitor assay 
(Roche). CD4 counts and p24 assays (Couker) were also performed. 
Samples were analyzed pre-immunization (baseline) and one month 
post-immunization. We had 90% power to detect a 1.23 log rise in 
RNA copy number. 
Results: 38/53 (72%) of those enrolled were receiving 
anti-retroviral therapy. 
in HIV Seropositiie Adults 
G. Poland', l? Mitchell ' , F! Wollan T. Smith I ,  
'Muyo Clinic, USA, 
Pre-immuniudon (man) Post-immunization (mean) 
HIV-1 R N A  capier/ml 15,556 
CD4 T-ceWd 289 




Conclusion: No statistically s i d c a n t  Merences were seen in 
HIV RNA copy number, CD4 count or p24 antigen level one 
month &r Hib-conjugate immunization. Subgroup analysis ac- 
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cording to Hib vaccine received or the presence or absence of 
anti-retrod therapy also failed to reveal any si&cant ditference. 
IP1046/ CD69 Expression as a Measure for Changes in 
Proliferation of Lymphocytes in HIV Infected 
Persons 
,I? Braun, M.N. Janssen, H. Knechten. Rmenzenftum BlondelstraJe, 
Aachen, Germany 
Objectives: To investigate the CD69 expression on T-lymphocytes 
h m  HIV-infected patients and to determine the correlation of the 
CD69 expression with the clinical features of disease progression. 
Methods: Heparinized whole blood was collected from 49 
healthy donors and h m  78 HIV-Ab+ persons which were in var- 
ious stages of disease [CDC 19931. Samples were incubated with 
and without Phytohemagglutinin (PHA), stained with FastImmune 
antibodies (BD) and analysed by flow cytometry. 
Results The percentage of CD3+CD4+ lymphocytes expressing 
CD69 after activation was slgruficandy lower in blood of HIV-Ab+ 
patients than in the samples of normal donors (p < 0.001). The 
percentage of CD3+CD8+ cells expressing CD69 was lower with 
and without activation by mitogen in comparison to the samples of 
normal donors (p < 0.05; p < 0.001 respectively), but there was 
no sipficant increase of CD8+ lymphocytes expressing CD69 (p > 
0.05) [see Table 11. Furthermore we observed a sigdcant decrease 
in the expression of CD69 on CD4+ lymphocytes by progression of 
disease 
Table 1: Expression of CD69 (mean, %) on CD4 and CD8 lymphocytes 
CD69 cxp-on Without PHA With PHA Inmare 
CD4 CD8 CD4 CD8 CD4 CD8 
N a r d  danon 5.5% 15.8% 42.1% 54.1% 37.3% 38.3% 
HIV Ab+ danon 7.2% 11.4% 30.5% 49.1% 23.3% 37.1% 
Conclusions: Our observations reveal a correlation of the various 
stages of HIV-infection with the expression of CD69 on stimulated 
T-lymphocytes. 
1 PI0471 A Whole Blood Assay to Detect T Cell 
Response to Antigens in HIV-1 Infected Patients 
S. Benyoucef', D. Hober', D. De Groote', X. De La 
Tribonniire 3, A. Bouzidi ', G. Lion ', P. Wattre 
Mrologie, C m ,  Lille, France, 'Meedgenix Diagnostics, Belgium, 'Hdpital 
de Tourcoing, France, 4L,FB, Lille, France, 'CH de Valenciennes, France 
Objectives: We developed an heparinized whole blood (HWB) 
assay to measure T cell medated immune responses to HIV and 
recall antigens. 
Methods: The cultures were performed in 96-well plates in 
which 25pl of whole blood was required. We studed the production 
of y and IL-4 in short term culture (24 and 48 h) of 1/10 diluted 
HWB cultures fiom 15 healthy controls and 43 HIV-1 infected pa- 
tients grouped according to 1993 classification of the CDC. IFN-y 
and IL-4 were measured with an immunoassay in supernatants of 
cultures, in the presence of supernatant of HIV-infected CD4 T 
cells, p24 HIV antigen, tubercuh (PPD), tetanus toxoid (TET) and 
phytoheamagglutinin (PHA). 
Results: We found no production of IFN-y and IL-4 in response 
to HIV-1 antigens in connols. A spec& IFN-y production in the 
presence of HIV antigen was obtained in 11/13 group A patients, 
13/21 group B patients and in 419 group C patients. In response to 
recall antigens (TET and PPD), we obtained IFN-y production in 
12/13 group A patients, 15/21 group B patients and in 319 group 
'Laboratoire de 
C patients, the response to PHA remained preserved until late in the 
disease. The production of IL-4 was tested in 22 patients included 
in the s t u d y .  Compared with the 15 conmls, high levels of IL-4 
associated with moderate or low IFN-y levels were found in 119 
group A patients, 2/8 group B patients and 4/5 group C patients, in 
the presence of HIV antigen, recall antigens and mitogen. 
Conclusion: Our results are in favor of a switch to Th2 type 
response in certain HIV (+) patients. The HWB assay is a quick 
and simple potentially valuable tool for assessing cellular immune 
function in HIV (+) patients. 
-1 Pitfells in Molecular Diagnosis of Human 
Immunodeficiency WNS TVpe 1 (HIV- 1) 
Infection and Determination of Viral Load in 
Patients Infected with HIV Strains of African 
Origin 
T. Bohler K.-M. Debatin 
'Kinderklinik, Universitut Heidelberg, Germany, 21rutitutfirr 
Medizinische Mrologie, Uniuersitat Heidelbus Germany, 
3~m-uon-~ettenkofer-fer-lns titut, Uniuersitiit Miinchen, Germany 
Background In infants born to HIVl' mothers qualitative 
and quantitative measurement of HIV-I nucleic acids (e.g., poly- 
merase chain reaction [PCR] or branched chain DNA hybridization 
[bDNA]) is now widely used for diagnostic purposes. We describe 
the influence of infection with Werent HIV I subtypes on the relia- 
bhty of molecular dngnosis in mother-child-pairs of hican origin. 
Methods: Proviral HIVZ sequences were identified in genomic 
DNA isolated h m  peripheral blood mononuclear cells (PBMC) 
and subjected to nested PCR using standard HIVI  PCR primers as 
described (Haas et al., J Infect Dis 1996; 174: 244). HIV-plasma viral 
load was quantified by reverse transcription (RT)-PCR (Amplicor 
HIV Monitor, Roche Diagnostics) as well as by bDNA detection 
(Quantiplex bDNA 2.0, Chiron Diagnostics). 
Results: In 6/13 patients infected with H I V I  strains of hican 
origin proviral HIV-I PCR was negative for gag, pol and env products 
(46% false-negative). In 4 out of 7 &can mother-child-pairs PCR 
could not be used for diagnosis of vertical HIV-transmission due 
to false-negative PCR results in PBMC fiom the mother. In all 
PCR-negative patients plasma viral load levels were undetectable 
by RT-PCR. In 2 patients bDNA was also not detectable (<500 
copiedml). 
Conclusion: Standard methods for molecular diagnosis of 
HIV-infection are based primarily on genomic sequences of HIT/- 1 
subtype B, the most abundant variant in Europe and the US. Their 
sensitivity for non-B variants is low and has to be improved by using 
reagents that are more spec& for these variants. 
M. Geiss ', I? Schnitzler ', J. Haas ' .  
I P1049 I NASBA Amplification Efficiency in African 
E. Gobbers ', K. Fransen ', T. Oosterlaken 
L. Heyndrickx ', R. Schoones ' , I? van de Wiel ' , G. van der 
Groen'. ' Organon Zknika, Turnhout, Belgium, z I d t u t e  of Tropical 
Medicine, Ant-, Belgium 
Objectives: To study the influence of the HIVl genetic variability 
on the efficiency of the HIVlRNA NASBA amplification system. 
Methods: Twenty diluted culture supernatants representing 17 
African HIVl M and 3 0 srrains were tested. NASBA RNA loads 
were compared with loads detected by RT-PCR (AmpLCor). The 
p24-antigen concentration and infective dose were determined. 
Results: NASBA quantified all HIVl M strains, except one, 
probably due to mismatches at critical primer annealing positions. 
Isolates Representing D*rent HlVl Subtypes 
W. Janssens ', 
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DSerences between NASBA and RT-PCR loads were observed for 
certain HIVl M strains.  Lower RT-PCR loads were measured for 
most gag A, gag B and gag F saainS, NASBA detected lower copy 
numbers in 1 gag C and 2 gag H strains. Some of these differences 
could be explamed by the presence and position of mismatches with 
primers. The hgher mismatch incidence of the Amphcor primers 
with gag A strains in general was probably responsible for the lower 
RT-PCR loads. Not all Merences could be exphned by the a d -  
able sequence information, but could result fiom an overestimation 
of the RNA load due to RT-PCR co-amplification of p r o d  DNA 
in supernatants, or an underestimation due to RT-PCR measure- 
ments outside the dynam~c range of the assay. HIVl 0 strains were 
hardly detectable by both amplification methods. No firm correla- 
tion could be observed between RNA loads and either p24-antigen 
or infective dose. 
Conclusions: NASBA was able to quantlfy representatives of d6- 
ferent HIVl M subtypes. Although both RNA quantitation assays 
use almost identical primers, differences in amplification efficiency 
were observed with regard to certain HIVl subtypes. 
[XI Gen-Probe Single Tube Quantitative HIV Assay 
S. Bodrug, R. Domingo, J Holloway, M. Sanders, K. Nunomura, 
C. Sloan, B. Billyrd. Gen-Probe Incorporated, San Diego, c4, U S A  
Objective: To develop a rapid, simple and sensitive viral load assay 
that is suitable for routine quantitation of HIV-1 RNA f h m  plasma 
in the clinical laboratory. 
Methods: Plasma samples are treated with a detergent solution 
to lyse virions, and genomic RNA is captured onto magnetic mi- 
cropartides. Plasma components and detergents are removed via 
wash steps. Transcription-Mediated Amplification (TMA) is used to 
a m p w  RNA target, followed by a homogeneous chemiluminescent 
detection assay (HPA). All steps are performed in a single tube and 
can be completed in 4 to 5 hours. 
Results. Assay performance w a s  evaluated with HMIIB spiked 
plasma panels containing 16 to 160,000 copies/mL and 12 patient 
specimens ranging in titer from 739 to 127,000 copies/mL. The 
quantitative range of this assay is 100 to 100,000 copies/mL plasma. 
Samples containing 50 copies/mL and 16 copies/mL produced pos- 
itive signals in 80% and 20% of the replicates, respectively We ob- 
served within run CVs to be t20% for spiked plasma and patient 
specimens containing >lo00 copies/mL, and approximately 30 to 
40% for spiked plasma containing (1000 copies/mL. The abdity 
to detect subtypes is increasingly important, and to date we have 
observed quantitative detection of subtypes A, C and E. Testing of 
other subtypes is in progress. 
Conclusions: With the advent of combination therapies that 
drive viral load to low levels, the Gen-Probe Quantitative HIV as- 
say provides the necessary sensitivity, reproducibility and dynarmc 
range to be useful in monitoring a patient’s disease progression or re- 
sponse to antiretroviral therapy. The single tube format permits high 
throughput and is compatible with automation. 
[q CD95 (Fa$)-Expression on CD4- and 
CD8-Lymphocytes of Progressors and 
Non-Progressors to AIDS 
T. Harr 
Swiss HIV Cohort Study (SHCS). ‘Institutfitr Medizinische 
Mikrobiologie, Universitiit Basel, Centre Hospitalier Univenitaire 
thudois, L u a n n e ,  ’Medizinische Poliklinik, Imekpital, Bern, 
Switzerland 
Objectives: To analyse the expression of the apoptosis-inducing 
J. von Overbeck ’, C. Kopp 3 ,  S. Lang ’, l? Erb for the 
CD95 and of CD26 on CD4+ and CD8+ lymphocytes in 
HN-infected long term survivors (LTS) in comparison to progres- 
sors and to u d e c t e d  controls. 
Methods: EDTA blood samples were collected fium the follow- 
ing HIV-infected individuals: 27 LTS (criteria: HIV+ >6 yrs, CD4 
>500, asympt.), 10 CDC stage A (A) and 10 CDC stage B/C PIC).  
10 non-infected individuals served as controls. Two and 3-color flow 
cytometry was performed using FITC-, PE- or PerCP-labeled mAb 
to CD4, CD8, CD26 and CD95. Results were statistically analysed 
using Students’ unpaired t-test. 
Results: CDI-population: The number of CD95+ cells was higher 
in HIV-mfected (66%) than in non-infected individuals (41%). LTS 
had similar numbers of CD95+ cells (55%) than A individuals (53%), 
whde B/C individuals were hghest (76%). The relative distribution 
of CD26+ cells was similar as with CD95, but inverse in the four 
groups (control 81%, LTS: 66%. A65%, B/C:34%). The difference 
between LTS and B/C was sigruficant. CD8-population: The num- 
ber of CD95+ cells was s& in LTS (55%). A (49%) and B/C 
(53%) indwiduals, all sigdicantly higher tban in controls (30%). In 
contrast, the number of CD26+ cells was sigdicantly lower in LTS 
(27%), A (20%) and B/C (16%) compared to controls (64%). 
Discussion: The expression of CD95 or CD26 on CD4+ or 
CD8+ cells of LTS was more similar to A or B/C individuals than 
to non-infected controls. 
Non-lnvasive Monitoring of HIV Viral Load in 
the Lymphoid Tissue by Lymph Node Needle 
Aspiration 
l?R.A. Meylan, €? Biirgisser, E-A. Bart, J.-Y. Meuwly, G. Pantaleo. 
ChTJlJ L u a n n e ,  Switzerland 
Goal: To evaluate needle aspiration for measuring the response 
to treatment of c d  subsets and viral load in the lymph nodes of 
HIV-infected individuals. We have demonstrated the feasability of 
th is  approach, and an increased CD4+/CD8+ ratio and viral load in 
the lymphoid tissue, compared to the blood (Meylan et al, JAIDS, 
1996; 13: 39-47). 
Methods: Repeated sampkng of lymph node cells (LNC) fiom 
nine antiretroviral-naive patients entering a double-blind s tudy  of 
zidovudine and/or zalcitabine and/or saquinavir were performed. 
LNC were obtained twice before, and 1 and 6 months after treat- 
ment start. Finger-guided fine (23G) needle aspiration using standard 
cytological technique. The needle was rinsed in anticoagulant fluid, 
the cells counted and characterized immunophenotypically by flow 
cytometry. HIV viral load was measured by QC-PCR for HIV gag 
DNA and RNA, and by a PCR specific for spliced RNA. 
Results: The effect of initiating antiretroviral treatment on viral 
load ranged fium no response to a dramatic decrease in plasma and 
LNC HIV RNA levels. The decrease in unspliced and spliced HIV 
RNAs in LNC was correlated with but consistently smaller (112 to 
1/3) than the decrease in plasma viremia. In the 2 patients with the 
deepest decrease in RNA levels, a strbng rise of the CD4+/CD8+ 
ratio was observed in the lymphoid tissue, suggesnng that rising 
CD4+ T cell numbers in the blood indeed reflect an increasing 
CD4+ T cell population in the lymphoid tissue as well. 
Conclusions: In these studies, finger-guided needle aspiration 
provided information regardmg CD4+/CD8+ ratios -and Wa load 
in the lymphoid tissue in about 50% of candidate patients. We are 
currently examining whether ultrasonic guidance will improve this 
success rate even in patients without palpable lymph nodes. 
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I PI053 1 Shedding of HIV-1 Subtype E in Semen and 
Cervico-vaginal Fluid 
R. Sutthent, F? Chaisilwattana, A. Roongpisuthipong, F? Wirajsilpa, 
K. Sumrangsurp, F? Chaiya!d, F? Puthavathana, C. Wasi. Siriraj 
Hospital, Mahidol Uniumity, Bangkok, Thailand 
Objectives: To determine whether high sexual infectivity of HIV-1 
subtype E in Thadand is due to the presence of virus in genital fluid. 
Methods: We conducted a study to characterize shedding of 
HIV-1 in seminal and cervico-vaginal fluids of 30 HIV-1 subtype 
E infected Thai couples, at age range 1 8 4 0  years, by PCR and 
virus isolation methods. None of the subjects in this study had 
HIV-associated diseases. HIV-1 subtype E was idenhfied by het- 
eroduplex mobility assay and peptide ELISA. HIV-1 proviral DNA 
in peripheral blood mononuclear cells, seminal cells, and C-V cells 
were quantitated. 
Result: HIV-1 subtype E DNA was detected in 22/30 (77.33%) 
of cervico-vagmal and also 22/30 (77.33%) of seminal fluid sam- 
ples. The isolation rate of HIV-1 fiom semen and cervico-vaginal 
secretion were 36.67% and 16.67%, respectively. Number of HIV-1 
subtype E DNA copies in blood is reversely correlated with num- 
ber of blood CD4 lymphocytes, while that in genital fluid was not 
related to blood CD4+ T cell count. 
Conclusion: An increase in sheddmg of HIV-DNA subtype E in 
female genital tract as compared to other HIV subtypes reported by 
other investigators might be one reason to explain the rapid spread 
of subtype E by heterosexuai transmission in Thailand. 
Viral Load and CD4+ T Cells as Predictors for 
Disease Progression in the Swiss HIV Cohort 
Study 
F! Erb ' , M. Egger ', M. Win ', M. Rickenbach for the Swiss 
HIV Cohort Study (SHCS). 'Department of Clinical Microbioloa, 
University o f h l e ,  Switzerland, 2Deparfment of Social and Preventive 
Medicine, University of Berne, Switzerland, 'Department of Social and 
Preventiw Medicine, University of lausanne, Sm'tzerland 
Objectives: To examine the prognostic sigNficance of serum viral 
load measurements, CD4 cell counts and other parameters in the 
SHCS. 
Methods: Vacutainer-CPT or EDTA blood samples were col- 
lected at regular follow-up visits. Kaplan-Meier lifetable methods 
and Cox regression models were used for statishcd analysis of sur- 
vival. 
Results: The analysis was based on 1278 participants with at least 
one viral load measurement. Mean age was 37.6 years, 71% were 
male, 28% had AIDS. Geometric mean viral load was 13,216 RNA 
copies/ml, mean CD4 cell count was 251 x 106/L. Relative risks 
(RR) were: 
RRf95% CI)' P m (95MCI)" P 
Log vral load 2.89 (1.74-4.81) 0.0031 2.60 (1.48-4.54) 0.001 
CD4 (per 100 cdlr) 0.46 (0.2W.74) 0.001 0.55 (0.344.89) 0.01 
~ ~~ 
adjusted for age, AIDS a d  yeu of cnrry, and viral load and CD4 cell count 
There was no statistically sigdicant interaction between d load 
and CD4 cell count. CD8 cell count upas no longer predictive once 
CD4 cell count had been included. Considerable loss of predictive 
power occurred when viral load and CD4 cell count were combined 
in a ratio (log RNA copies per ml/CD4 cells x 106/L) 
Conclusions: Viral load and CD4 cell count are independent 
predictors of the risk of death. 
CD4+ T-cell Apoptosis in Human 
Immunodeficiency WNS (HIWj-Infection 
Conelates with Disease Stage but Not with 
Viral Load 
T. Bolder ' , J. Walcher ', M. Geiss ', I. Herr ', K.-M. Debatin ' 3. 
'Kinderklinik, Universitiit Heidelberg, Germany, 'Institutjkr 
Medizinische Virologie, Universitiit Heidelbq, Germany, 'Molekulare 
Onkologie, DKFZ Heidelberg, Germany 
Background Increased apoptosis of CD4' T cells is thought to 
be involved in CD4+ T helper cell depletion in HIV-1 infected 
individuals. The CD95 (APO-l/Fas) receptor/ligand (L) system, a 
key regulator of apoptosis in normal and malignant T cells, is pro- 
foundly deregulated in peripheral blood T cells during HIV-1 in- 
fection (Blood 1994; 83: 3101; Blood 1996; 88: 1741). It is not 
known, however, how T cell apoptosis and deregulation of the 
CD9WCD95L system are related to HIV-1 plasma v i ra l  load and 
to &ease progression. 
Methods: CD95 expression on peripheral blood T cells fiom 
HIV-1' children and T-cell apoptosis induced by immobilized 
anti-CD3 or anti-CD95 antibodies were assessed by flow cytom- 
e q .  CD95L expression in keshly isolated peripheral T cells was 
measured using quantitative RT-PCR. HIV-1 plasma viral load was 
measured by branched DNA determination (Quantiplex bDNA 2.0, 
Chiron Diagnostics). 
Results: CD95 expression in T-cells increased with disease pm- 
gression (indicated by decreasing CD4' T cell counts). Anti-CD95- 
and anti-CD3- (activation-) induced cell death (AICD) of CD4+ 
T cells also increased with disease progression. No correlation was 
found between H I P 1  plasma viral load and any of these parameters. 
However, a reduction of both CD95L levels and in vim CD4' T 
cell apoptosis was observed during antiretroviral treatment. 
Conclusion: Increased AICD and deregulation of the CD95 re- 
ceptodligand system in T cells fiom HIV-1-infected children in- 
crease with advanced CD4+ T cell loss. The effect of antiretroviral 
combination therapy on &ease progression may partly be explained 
by reduced AICD of CD4+ T cells during therapy. 
Ip10561 A Controlled Trial of ddl Plus d4T. Plus 
Hydroxyurea or Placebo, in HIV Infection 
O.T. Rutschma~,  M. Oprad, A. Iten, R. Maltnverni, P Vernazza, 
H. Bucher, E. Bernasconi, S. Vincent-Surer, V. Gabriel, L. Perrin, 
S. Yerly, B. Hirschel for the Swiss HIV Cohort Study (SHCS). 
University Hospital, Division ofInJedoLI1; Diseasec, Geneva 14, 
Switzerland 
Objective: To assess the short-term effects on viremia and CD4 of 
ddl + d4T f hydmxyurea in HIV infected patients. 
Methods: 141 patients (80% antiretrovirally naive, 25% female,) 
have been randomized to receive ddl200 mg bid + d4T 40 mg bid 
+ placebo (P) or ddl + d4T + hydmxyurea (HU) 500 mg bid in 
an ongoing study. Evaluation (cknical, viremia poche  assay], CD4) 
was obtained at baseline and at 4 and 12 weeks. 
Results: Twenty patients stopped therapy due to nausea (6), neu- 
ropathy (2), psychlatric disorder (l), nail dystrophy (l), patients' de- 
cision (2), lost to follow-up (8). Results at week 12 are presented in 
PYvneccr Basehe (mean f SE) A IC Week 12 p H U v r P  
N = 141 N = 81 
Log RNA 4.5 k 0.05 H U  -2.O/P -1.7 0.12 
w c m a  ncganve (-200) 0% Hu: 56%/P: 40% 0 07 
CD4/mm3 362 f 10 H U  +7/P: +89 0.004 
CD8/mm3 1030 f 45 Hu: -212/P -50 0.07 
Total lymph0cyrer/mm3 1803 f 58 H U  -225/P +73 0.02 
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the table. 
Conclusion: Hydroxyurea margudy increases the effect of ddl 
+ d4T on plasma viremia. However, the addition of hydroxyurea 
causes lymphopenia and abolishes beneficial effect of dill + d4T on 
the CD4 count. 
m1 Escape of Viremia and Rapid Development of 
Protease Gene Mutations in Advanced H N  
Infection Treated with Saquinavir and Rionavir 
P. Lorend', S. Yerli I. Overbeck ', 
B. Hinchel'. ' Hdpital Uniuersifaire de G n h ,  Lausanne, Switzerland, 
' Cenhe Hospitalier Univmifaire Vaudois, Lauranne, Switzerland 
Objectives: To assess the efficacy, safety and pharmakokinetics of 
the combination of ritonavir and saquinavir for the treatment of 
advanced HIV infection. 
Methods: Pilot Study. 18 antiprotease-naive patients with 1 to 50 
CD4 cells were treated with 600 mg twice daily of both ritonavir 
and saquinavir. HIV viremia, CD4+ and CDS+ cells count were 
determined at week 5, 9 and 13. HIV proteinase gene mutations 
were determined in case of non response. Drug levels were measured 
after at least 3 weeks of combined treatment. 
Results: 1 patient died early h m  TB, 1 stopped because o f t  
amylase and t tnglycerides, leaving 16 patients evaluable at week 5. 
11 patients responded at week 5 (Rs > 1 log drop in viremia): among 
these, 1 rose back to baseline at week 9 (poor compliance), 6 stopped 
treatment because of side-effects (1 hepatitis, 1 paresthesias), patient 
choice (3) or study violation (1). Plasma ritonavir and saquinavir 
levels were lower in non responders (NRs) than in Rs (p < 0.03). 
However, some NRs had saquinavir levels exceeding the in vitro 
MIC5O by more than 50 times. The protease gene in NRs revealed 
multiple mutations at positions 10, 16, 36,48, 63, 64, 82, 84, and 90 
after 9 weeks of treatment, most of whch were not present at time 0. 
Conclusion: the response to rit and saq in advanced HIV in- 
fection is unpredictable. Escape of viremia and rapid development 
of multiple protease gene mutations suggest early resistance in some 
patients. 
0. Rutschmann ', M. Fathi 
I P1058 I The Product of Human Cytomegalovirus 
(HCMV) UL44 Downregulates HN-1 LTR 
Transactivation Mediated by HIV-Tat and 
HCMV-IE1 /IE2 
M.C. Boccuni, E Camp-, M.C. Battista, I! Dal Monte, 
G. Bergamini, A. Ripalti, M.P. Landini. Depurfment of Clinical G 
Experimental Medicine, Division of Mimbiology, University of Bologna, 
Bologna, Italy 
Objectives: While incomplete expression of the HCMV genome 
leads to activation of the HIV-LTR because of the transactivation 
activity of IEl/IE2, a complete expression of the HCMV genome 
inhibits HIV replication. This study aimed at determining which 
HCMV gene@) has a negative effect on HIV-LTR. 
Methods: Cotransfection experiments were carried out in J-Jhan 
and U937 cells using different expression vectors and the reporter 
construct HIV-luc which expresses the luciferase gene under the 
control of HIV-LTR. 
Results. The product of HCMV UL44 (ppUL44, a 
DNA-binding protein of 52Kd, essenaal for HCMV replication) 
strongly downregulates the HIV-LTR aansactivation mediated by 
both HIV-Tat and HCMV-IEWIE2 both alone and in synergy. 
ppUL44 deletion mutants showed that the active portion is located 
within the last 114 aminoacids at the C' terminus of the molecule. 
HIV-LTR deletion mutants showed that the NF-kB binding region 
is necessary for ppUL44 downregulation. 
Conclusions: We have idenbfied a HCMV gene which encodes 
for a protein that has a negative effect on HIV-LTR transactivation. 
Studies are in progress to understand the mechanisms of the inhibi- 
tion. 
[P1059 I Stadi Pilot Study: Once Daily Administration of 
DDI in Combination with D4T in Antiretroviral 
Naive Patients 
J. Reynes ', R. Denisi ', A. Bicar-See ', B. Delmas', M. Dupon ', 
J. Peceny ', J.J. Gres ', P. Ngo Van ', J. Izopet ', B. Montes I ,  
I. Pellegrin', M. Segondy for the Stadi Group. 'Montpellier, 
Uniumity Hospital, France, 'Bordeaux, University Hospital, France, 
Toulouse, Univmify Hospital, France, 'Brisfol-Myers Squibb, France 
Objective: To evaluate the a n t i 4  and immunological effects, and 
the tolerability of hdanosine (ddI) given once-daily in combina- 
tion with stavudine (d4T) in naive patients @a) with 100 to 500 
CD4/mm3. 
Methods: 52 HIV-infected adults (CDC A = 33; B = 14; C = 5) 
were treated with d4T (40 mg BID) and ddl (300 mg once a day) (if 
weight t 6 0  kg: 30 mg BID and 200 mg QD respectively). 
CD4 and HIV-RNA (Quantiplex@ HIV-RNA 2.0; assay detec- 
tion limit, 500 copies/ml) determinations were carried out at Weeks 
0, 4, 8, 16, 24. 
Results: 
(n P*) Baseline W4 wa W16 
Mcm CD4 330 (52) 432 (50) 429 (43) 439 (28) 
Mean log RNA 4.48 (50) 2.98 (48) 2.94 (47) 3.06 (34) 
ARNNbucLne - 1.50 (48) 1.55 (47) 1.42 (34) 
% Undetectable o (50) 66.7 (48) 72.3 (47) 76.5 (34) 
Six pts disconiinued the study due to poor comphce  (2 pts), 
own request (1 pt) and adverse events (3 pa). 
Conclusion: This hial is the first to use ddI at a once-a-day 
dosing in combination with d4T. The interim analysis shows that 
this therapy is well tolerated, has a potent immunological effect and 
a high antiviral efficacy. 
Ip10601 Once-Daily Administration of Didanosine in 
Combination with Zidovudine in Naive 
HIV-Infected Patients 
J. Reynes, B. Delmas, B. Montes, I. Pages, M. Segondy. Cenfre 
Hospitalier Uniwrsifaire de Montpellier, Frunce 
Objective: To evaluate the efficacy of a zidovudine/didanosine com- 
bination therapy in which mdanosine was admintstered once daily. 
Methods: Twenty-five an t i re t rod  naive patients (CDC A = 10; 
B = 9; C = 6) were included and followed up over 6 months. 
Didanosine was administered at a dosage of 300 mg (200 mg 
if weight <60 kg) once a day and zidovudine at a dosage of 250 
mg (300 mg if weight >60 kg) twice a day. CD4 and HIV-RNA 
(NASBA HIV-1 QT assv, detection limit: 400 copies/ml) dctermi- 
nations were carried out at Weeks 0,8,24. 
Results: Twenty patients were evaluable for efficacy. The HIV-1 
RNA level at entry was 5.42 f 0.56 log copies/ml. The decrease in 
HIV-1 RNA level h m  baseline was 2.30 f 1.35 log copies/ml at 
W8 (range, +0.77 to -4.59) and 2.14 f 0.98 log copies/ml at W24 
The CD4+ count at entry was 278 f 181 ceIls//.~I. The mean 
increase was 102 cells/hl at W8 and 156 cells/Fl at W24. Five 
patients discontinued before W24 (poor compliance, 3 pts; adverse 
(range, -0.55 to -3.81). 
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events, 2 pts). 
Conclusion: Once-daily administration of didanosine appears to 
be as effective as twice-daily admuustration in zidovudine/&dano- 
sine combination therapy. 
PI061 1 lndinavir (IDV) Phamacokinetics (PK) in 
HIV-Infected Children Receiving Combination 
Therapy with Stavudine (d4T) and Didanosine 
(ddl) 
C.V. Fletcher, M.W Kline, R.C. Brundage, A.T. Harris, L.M. Page, 
D. Weller, R.P Remmel, WT. Shearer. Univ ofMinnesota, 
Minneapolis, M N ,  USA, Baylor College ofMedicine, Houston, TX, 
USA 
Objectives: We designed studies to evaluate IDV PK in 
HIV-mfected children receiving IDV+d4T+ddI theram. 
Methods In 5 children, IDV was given alone on day 1 and then 
simultaneously with d4T and ddI on day 2. Serial blood samples 
were obtained over 4 hours and analyzed for IDV, d4T, and ddI con- 
centrations with HPLC. Mean (and % CV) IDV CL/F when given 
alone was 2.1 (75%) Lkg/h, and with d4T+ddI was 1.7 (79%) 
L/kg/h. IDV+d4T+ddI administration did not appear to aEect ad- 
versely IDV bioavailability, and we proceeded with a PK evaluation 
of IDV+d4T+ddI therapy in 12 chlldren (indudmg the 5 above). 
One timed blood sample was obtained at least every 4 weeks for 
IDV, d4T, and ddI. IDV doses were adjusted iftrough concentrations 
were t l O O  ng/mL. 
Results: 60 concentrations obtained during 12 weeks of 
IDV+d4T+ddI therapy were analyzed with the nodnear 
mixed-effects model program NONMEM to determine IDV PK 
in these 12 children. A 1-compartment oral absorption model with 
an absorption lag time was fit to a l l  data simultaneously. Typical PK 
parameters were iteratively estimated to be CL/F = 1.1 L/h/kg; V/F 
= 2.3 L/kg; Ka = 1.9 hr-1; Tlag = 0.8 hr. Residual variabikty was 
25%. Interpatient variability was high with Bayesian post-hoc val- 
ues for CL/F ranging from 0.6-3.2 L/h/kg. Nine of 12 children 
required adjustment of their IDV regimen to q6h as trough values 
were <lo0 ng/mL.. IDV in CSF was measured in 4 children with 
concentrations of 151-977 ng/mL. 
Conclusions: IDV PK in these children were highly variable; 
most children will have trough values c l 0 0  ng/mL with a regimen 
of 500 mg/m2 q8h. Concentration-guided dosing of IDV may be 
necessary for an ophmal anti-HIV effect, and can be used since 
intraindividual variability was modest. 
Supported by: NIAID RO1 A133835 
[-/ Phagocytosis of E. coliand S. aureus by 
Neutrophils of HIV-Infected Patients 
R. Schaumann, J. Krosing, PM. Shah. Universitiitsklinikum, 
ZZM/Med. Klinik ZZI/Znfektiologie, 0-60590 Frankfurt, Germany 
Objectives: To study the influence of HIV infection on phagocyto- 
sis of E .  coli and S. aureus by polymorphonuclear leukocytes (PMN) 
in vim. The results of phagocyte function studies in HIV-infected 
patients have been contradictory. 
Methods: PMN were isolated from the blood of 25 HIV-infected 
patients (group 1: CD4 t 25O/pl 14 patients, p u p  2: CD4 > 250 
p1: 11 patients) by Percoll density gradient and incubated with E .  
coli and S. aureus. Subculture technique was used to determine PMN 
function at 0,0.5, 1, 2,4, 6, and 24 hours. Controls were run with 
PMN &om healthy volunteers. 
Results: Table of contingency for the gmwth of E. coli and S. 
aureus incubated with PMN after 24 hours. 
CDI < 25O/ul CD4 > 250/wI Total 
Growth of E. colt (99) 
< 6 x lo3 4 
> 6 x l d  10 
Total 14 
Grow& of S. ~ U ~ U S  (99)
< 3.5 x lo3 3 














Conclusions: Phagocytosis of E.  coli and S.a urew by PMN 
of HIV-infected patients was sigdicantly lower in group 1 (p 
< 0.05). Reduced phagocytosis of E .  coli and S. aureus was 
found in HIV-infected patients with low CD4-cell counts. This 
may contribute to increased susceptibility to bacterial infection in 
HIV-infected patients with low CD+-cell counts. 
PI063 I Targeting to the HN-1 RRE of the Influenza 
Virus NS-1 Protein Effector Domain as a Potent, 
Specific Anti-HIV Agent 
M.-J. Zhang, A.I. Dayton. CBER,  FDA, Bethesda, Maryland, USA 
Objectives: To improve the trans-dominant negative inhibitory ef- 
ficiency of the M10 mutant of the HIV-1 Rev gene. 
Methods: The Rev axis of HIV autoregulation is one of two 
critical viral regulatory pathways required for expression of viral 
genomic and mRNA and for replication. Consequently it is an 
attractive therapeutic target. Previous studies have investigated the 
anti-HIV efficacy of targeting to the RIlE (the viral RNA target se- 
quence of the Rev axis) a trans-dominant negative lnhibitor mutant 
Rev, M10. In this study we have fused a portion of the infulenza 
virus NS1 protein which normally inhibits poly A(+) mRNA trans- 
port, to the Rev M10 gene while deleting the NS1 poly(A) binding 
region. 
Results The resulting chimera demonstrates specific and en- 
hanced inhibition of viral-RRE-containing RNA Expression. 
Conclusions: The M10-NS1 chimera is a potent, specific 
anti-HIV agent. 
I PI064 1 Enhancement of HIV-1 Replication and 
Protection of CD4+ Cell-Depletion by Diglucosyl 
Diacylglyceride (DGDG) 
S .  Ono, S. Arai. Dqt.  Bacfm'ol. Kurume Uniu Sch. Med. Kurume, 
Japan 
Objection: To examine the enhancement of HIV-1 replication and 
the protection of CD4 cell-depletion by DGDGs. 
Methods: MOLT4 and MT-4 cells were freshly infected with 
HIVIIIB. CD4' cells were determined by direct immunofluorescent 
method using cell analyzer. p24 antigen was assayed by ELISA sys- 
tem. DGDG was purified from Acholeplusma laidlawii by silica gel 
chromatography and NMR. Also synthesized DGDGs (C14, C16) 
were used in this experiment. 
Results: Both of DGDGs obtained from A. Zaidlawii membranes, 
and synthesized DGDGs (C14, C16) increased p24 antigen in the 
HIV-infected cells. Amounts of $4 in the supernatants of MOLT-4 
cells were 1455, 120, 1060 pg/ml, and p24 in those of MT-4 cells 
were 3000,3750,1430 pg/ml in the presence of 1 mcg/ml of native 
and DGDGs (C14, 16). Value of p24 without DGDG was less than 
450 p g / d  in each experiment. The enhancement of p24 began 
on day 6 and reached a h u m  on day 10. The enhancement 
was dose-dependent When HN-infected cells were cultured in the 
presence of 10 mcg/ml of native DGDG, and synthesized DGDGs, 
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% of CD4+ cells remained in 22,28,32% respectively (p < 0.001). % 
of CD4+ cells infected with HIV-1 were 9% and % of CD4 without 
the infection, was 35% (p < 0.001). 
Conclusion: Glycolipids in the microorganism membme par- 
ticipate in the HIV replications and regulation of CD4* molecules. 
1 PI065 I Study of AZT and AMT Plasma Concentrations 
and their Relationship with Haematological 
Toxicity 
V. Schaeffer’, L. Belfayol-Pisante ’, F! Alet ’, E Fauvelle ’, 
M. Echard 
Mon@rmeil, fiance, ’H6pital Avicenne, Bobigny, France 
Objectives: The aim ofthis study was to investigate ifHIV-positive 
patients developing haematological toxicity are exposed to higher 
plasma concentrations of 3’-azido-3’-deoxythymidine (AZT) and 
3’-amino-3’-deoxythymidine (AMT), a cytotoxic metabolite of 
AZT. 
Methods: Thirty-three HIV-positive patients were studied. Age, 
sex, weight, disease stage, other associated therapeutics, liver func- 
tion, haematological cell counts and serum hemoglobin level were 
noted for all patients. AZT was administered orally in doses of 300 
to 750 mg twice or thrice daily regimen. Blood samples were taken 
just before (TO) and one hour after (T60) the admimstration. A sen- 
sitive high-performance liquid chromatographic assay has been used 
to determine the levels of AZT and Ah4T in human plasma. 
Results: 79% of patients developed anemia (Hb -= 13 g/lOO ml 
in man). 30% developed neutropenia (neutrophiles -= 1800/p1). The 
mean TO and T60 concentration of AZT were, respectively, 32.8 f 
38.9 (10-178) n g / d  and 822.4 f 800.3 (47-3603) ng/ml. AMT 
was not detected at TO and the mean T60 concentration of AMT 
was 7.5 f 2.3 (5.0-12.6) ng/ml. We don’t tind any sigruficative 
Werence (Student t test) in the AMT and AZT concentrations 
between patients with anemia or neutropenia and those without. 
Conclusion: AZT TO concentrations observed are lower than 
those previously reported in others studies. Therefore, this preluni- 
nary results showed that doses and schedules of AZT don’t provide 
optimal concentrations, particularly at TO. There are no quantita- 
tive relationship between AZT or AMT concentrations and toxicity. 
Further data would be necessary to show if higher concentrations 
produce more haematological toxicity. 
M. Bentata ’. ’ Centre Hospitalier Intercommunal de 
Blood cultures II 
I PI066 I Clinical Significance of Positive Blood Cultures 
Due to Streptococci of the Viridans Group 
W G )  
D. Dalmau, L. Gbmez, M. Rodriguez, M. Salavert, C. Skchez, 
M. Xercavins, J. Garau. Hospital M h a  de Tenassa, Barcelona, Spain 
Objectives: To ascertain the c h c a l  sigdicance of positive blood 
cultures (PBC) due to SVG and to compare them with those due to 
S. milleri group (SMG). 
Methods: From 1988 to 1996 we identifed 149 episodes ofSVG 
among a total of 2068 PBC in hospitalized patients recorded in our 
institution. Episodes were classified as: a) contaminant, b) transient 
bacteraemia, c) estabhshed infection. 
Resulw Ninety-nine (53%) episodes were classified as contam- 
inants, defined as a single PBC with lack of clinical correlation, 
whereas 50 episodes (34%) were considered chically sipficant. 
Among these, 27 (54%) were self-limited and did not require specific 
treatment (transient bacteraemia). The remaining 23 episodes had a 
consistent dinical picture with well established streptococcal infec- 
tion, requiring antibiotic theraw. The most prevalent species were 
S. sanguis (35%), S. mitis (26%), S. saliwrius (9%) and Sfrep- sp. 
(26%). The primary source of SVG bacteraemia was endocarditis in 
7 (30%) - all of them having prior cardiac valve &ease - abdomuul 
in 5 (22%), vascular in 4 (17%), respiratory in 3 (13%), neck abscess 
in 2 (10%) and urinary and skin in 1 (4%) case respectively. PBC 
due to SMG (n = 37) were always chically sigNficant and strongly 
correlated with an underlying abdominal suppurative process (62% 
vs. 17% observed in SVG; O R  7.8; p = 0.001) whereas endocardi- 
t i s  was observed more frequently in PBC due to SVG (30% vs. 3% 
observed in SMG; OR: 15.7; p = 0.003). 
Conclusions: Among PBC due to SVG, almost one thud of the 
total episodes were clinically sigtllficant. Halfofthese episodes did not 
require treatment. Contamination of PBC due to SVG is not unusual 
and might be considered whenever a smgle blood culture is positive. 
In contrast, PBC due to SMG are always chcally sigtllficant. 
1 PI067 I Enterococci in Blood Cultures 
M. ~ r o n k ,  A. Samet, A. Sle&ka, E. c z a m d .  Department o j  
Clinical Bactm‘ology, State Clinical Hospital hp 1 in Gdansk, Poland 
Objectives: The aim of t h i s  study was to evaluate enterococcal bac- 
teremia. Enterococci have become important nosocomial pathogens 
despite their low virulence. We report the epidermology and the 
susceptibllity patterns of these strains isolated in our hospital. 
Methods: A total of 11 429 aerobic and anaerobic Bact/Aiert 
(Organon T e e  Corp. Durham, N.C.) bottles were processed be- 
tween 01.01.1994 and 31.12.1995. Enterococci represented 4.2% 
(90 strains)  of all isolates (2119 strains). 
Results: During two year period we isolated 72 E. faecalis 
(80.0%), 11 E. faecium (12.2%), 4 E.  auium (4.4%) and 3 E. durans 
(3.3%). 
Enterococci were isolated from: 
Hematology Unit 26 (28.8%) 
Intensive Cue Unit 24 (26.m) 
surgrry Unit 18 (2O.W) 
General Unit 15 (16.7%) 
Pcdiatric Unit 7 (7.E%) 
The percentages of susceptibility to antibiotics were: ampicillin 
83.9%, gentamicin H.L. 40.2%, streptomycin H.L. 30.6%. No one 
of these strains represented vancomycin or teicoplanine resistance 
phenotype. 
Conclusions: E. fmcalis and E. faecium are hquently isolated 
from blood. There is a high level of aminoghcoside resistance among 
blood isolates. AU strains isolated from blood are susceptible to van- 
comycin and teicoplanine. 
I PI068 1 The E M  of Clinically Significant Anaerobic 
Blood Culture on Antimicrobial Therapy and 
Patient Outcome 
J. Salonen, 0. Meurman. Clinical Minobiology Turku University 
Central Hospital, Turku, Finland 
Objectives: To evaluate the sigtllfcance of anaerobic blood culture 
and its effects on clinical decision makmg. 
Methods: Positive anaerobic blood cultures from a five year pe- 
riod (1991-1995) were collected from laboratory data. The patient 
records were analysed retrospectively using preformed criteria to 
evaluate the sigNficance of the fin- and the effect of the lab- 
oratory result to the patients’ treatment and outcome. 
